“The global needle free injection market is expected to grow at a CAGR during the forecasting period (2021-2028)”.
Needle-free injection (NFI) is a relatively newer technology that delivers drugs or vaccines either intramuscularly or subcutaneously using a narrow, precise fluid stream. Several benefits of the needle-free injection system include self-administration of medications and elimination of needle phobia. Needle free injection systems encompass a wide range of drug delivery systems. Highly viscous drug administration is possible which cannot be administered by traditional syringe systems.
Download free sample: https://www.datamintelligence.com/download-sample/needle-free-injection-market
The global needle free injection market growth is driven by the rising demand for vaccinations and biosimilars, instant drug delivery technology, increasing rate for self-injection devices, and growing chronic diseases.
The increasing incidence of communicable disease due to needle stick injuries
Needlestick injuries are frequent occurrences in healthcare settings and can lead to serious complications. While the introduction of universal precautions and safety conscious needle designs has led to a decrease in needlestick injuries but still do occur. Awareness of needlestick injuries started to develop soon after the identification of HIV. However, today the major concern after a needlestick injury is not HIV but hepatitis B or hepatitis C. Guidelines have been established to help healthcare institutions manage needlestick injuries and when to initiate post-exposure HIV prophylaxis. The Centers for Disease Control and Prevention (CDC) has developed a model that helps healthcare professionals recognize when to start antiretroviral therapy.
Nurses were the most affected staff resulted commonly from disposing syringes. In contrast, the incidence of NSIs among physicians was where surgical devices were the primary source of NSIs has greater among them. Thus the growing insidence of communicable disease due to needle stick injuries is driving the growth of the market in the forecast period.
Increasing demand for self-injection devices is driving the growth
Self-Injection devices allow patients with chronic diseases to gain control of their treatment schedule and their treatment setting, thus allowing greater independence and freedom in their social, domestic and professional lives. Self-injection may also offer psychological benefits over administration by healthcare professionals, including improved self-esteem. Removing the need to attend a clinic or hospital for regular injections also brings economic benefits to both the patient and the healthcare system. This economic benefit of self-injection devices has been the major growth driving factor for needle free injection market. Increasing prevalence of chronic autoimmune diseases like rheumatoid arthritis and cancer have also helped the growth as self-injections have application in recovery from these illnesses. These factors are driving the growth of the marrket in the forecast period.
Global Needle Free Injection Market– By Type
Global Needle Free Injection Market- By Application
- Vaccine Delivery
- Insulin Delivery
- Pain Management
Global Needle Free Injection Market– By End-User
- Home Care settings
Global Needle Free Injection Market- By Region
- North America
- Middle East & Africa
- South America
The needle free injection market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Endo International, PharmaJet, Fierce Pharma, Medical International Technology, INJEX Pharma, National Medical Products, European Pharma Group, PenJet Corporation and Crossject among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anal fistula globally. For instance, in October 6, 2020, Pharma Jet, Straits Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial in Australia. The DNA-based vaccine COVIGEN was developed by French-Thai pharmaceutical company BioNet and Melbourne-based biotech Technovalia.
Sai Kiran Sales Manager at DataM Intelligence Email: [email protected] Tel: +1 877 441 4866 Website: www.datamintelligence.com